Regulatory NewsBREAK: CMS Issues Final Negotiated Prices for Initial Price Applicability Year 2026
On Aug. 15, 2024, the Centers for Medicare & Medicaid Services (CMS) issued the Final Negotiated Prices for Initial Price Applicability Year 2026 under the Inflation Reduction Act (IRA). The drugs selected for this negotiation are Januvia, Fiasp, Farxiga, Enbrel, Jardiance, Stelara, Xarelto, Eliquis, Entresto, and Embruvica. Access the Regulatory NewsBREAK to learn more.
Related
On September 30, 2025, the White House announced a deal with Pfizer to lower drug costs in line with most-favored nation (MFN) pricing. While specific terms of the agreement have not been disclosed, both Pfizer and the White House issued statements providing a broad outline of the agreement.
On September 22, 2025, President Trump claimed that acetaminophen, the active ingredient in Tylenol, taken during pregnancy increases the risk of autism. Acetaminophen has long been considered one of the few safe options for treating pain or fever during pregnancy.
On Sept 18 and Sept 19, 2025, the Advisory Committee on Immunization Practices (ACIP) met to review data and vote on vaccine recommendations.
Featured News & Resources
See Full Calendar
Other Events
Award Applications Open
Webinars
AMCP eLearning Day: Nexus Encore
National Meetings
AMCP 2026 Registration Opens
Upcoming Events
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.
